​

Nuvalent (NUVL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NUVL Stock Forecast

Nuvalent (NUVL) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $137.44, with a high of $155.00 and a low of $120.00. This represents a 34.40% increase from the last price of $102.26.

$65 $83 $101 $119 $137 $155 High: $155 Avg: $137.44 Low: $120 Last Closed Price: $102.26

NUVL Stock Rating

Nuvalent stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 14 Strong Sell Sell Hold Buy Strong Buy

NUVL Price Target Upside V Benchmarks

TypeNameUpside
StockNuvalent34.40%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--12
Avg Price Target--$132.83
Last Closing Price$102.26$102.26$102.26
Upside/Downside--29.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26414---18
Feb, 26414---18
Jan, 26414---18
Dec, 25414---18
Nov, 25511---16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 24, 2025Truist Financial$140.00$105.8832.23%36.91%
Nov 17, 2025Etzer DaroutBarclays$152.00$108.0040.74%48.64%
Nov 17, 2025Leerink Partners$149.00$110.5634.77%45.71%
Nov 17, 2025H.C. Wainwright$155.00$110.6040.14%51.57%
Nov 12, 2025Canaccord Genuity$126.00$96.1631.03%23.22%
Oct 31, 2025Goldman Sachs$120.00$98.1722.24%17.35%
Oct 31, 2025David DaiUBS$132.00$98.1734.46%29.08%
Oct 27, 2025Kelsey GoodwinPiper Sandler$128.00$93.3937.06%25.17%
Oct 15, 2025Josh SchimmerCantor Fitzgerald$135.00$89.3551.09%32.02%
Sep 03, 2025Guggenheim$122.00$79.5453.38%19.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 17, 2025UBSBuyBuyhold
Nov 17, 2025H.C. WainwrightBuyBuyhold
Oct 31, 2025Goldman SachsBuyBuyhold
Oct 31, 2025UBSBuyBuyhold
Oct 31, 2025BarclaysOverweightOverweighthold
Oct 27, 2025Piper SandlerOverweightOverweighthold
Oct 15, 2025Cantor FitzgeraldOverweightinitialise
Sep 02, 2025Raymond JamesOutperforminitialise
Jun 24, 2025H.C. WainwrightBuyBuyhold
Dec 30, 2024H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.17$-3.93$-5.85---
Avg Forecast$-2.15$-3.91$-4.51$-4.77$-2.80$-0.70
High Forecast$-2.08$-3.53$-3.96$-2.88$-0.50$-0.70
Low Forecast$-2.21$-4.21$-5.52$-6.59$-5.19$-0.70
Surprise %0.93%0.51%29.71%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$6.25M$36.55M$217.26M$365.44M
High Forecast--$6.25M$37.08M$217.26M$365.44M
Low Forecast--$6.25M$36.01M$217.26M$365.44M
Surprise %------

Net Income Forecast

$-450M $-360M $-270M $-180M $-90M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-126.22M$-260.76M$-425.38M---
Avg Forecast$-126.22M$-224.28M$-312.31M$-330.80M$-237.45M$-40.58M
High Forecast$-120.93M$-205.28M$-230.42M$-167.53M$-28.96M$-40.58M
Low Forecast$-128.56M$-245.39M$-321.42M$-383.72M$-302.26M$-40.58M
Surprise %-16.26%36.21%---

NUVL Forecast FAQ

Is Nuvalent stock a buy?

Nuvalent stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nuvalent is a favorable investment for most analysts.

What is Nuvalent's price target?

Nuvalent's price target, set by 14 Wall Street analysts, averages $137.44 over the next 12 months. The price target range spans from $120 at the low end to $155 at the high end, suggesting a potential 34.40% change from the previous closing price of $102.26.

How does Nuvalent stock forecast compare to its benchmarks?

Nuvalent's stock forecast shows a 34.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nuvalent over the past three months?

  • March 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Nuvalent’s EPS forecast?

Nuvalent's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.77, marking a -18.46% decrease from the reported $-5.85 in 2025. Estimates for the following years are $-2.8 in 2027, and $-0.7 in 2028.

What is Nuvalent’s revenue forecast?

Nuvalent's average annual revenue forecast for its fiscal year ending in December 2026 is $36.55M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $217.26M, and $365.44M for 2028.

What is Nuvalent’s net income forecast?

Nuvalent's net income forecast for the fiscal year ending in December 2026 stands at $-331M, representing a -22.23% decrease from the reported $-425M in 2025. Projections indicate $-237M in 2027, and $-40.576M in 2028.